The apolipoprotein E ε2 allele and decline in episodic memory

Journal of Neurology Neurosurgery and Psychiatry

Volumn 73, Issue 6, 2002, Pages 672-677

  Wilson, R S ^a   Bienias, J L ^a   Berry Kravis, E ^b   Evans, D A ^a   Bennett, D A ^a  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

^b RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN E; APOLIPOPROTEIN E2; APOLIPOPROTEIN E3; APOLIPOPROTEIN E4;

ADULT; AGED; ARTICLE; COGNITION; CONTROLLED STUDY; DEPTH PERCEPTION; DETERIORATION; FEMALE; GENE FREQUENCY; GENOTYPE; GROWTH CURVE; HUMAN; MALE; MEMORY; PRIORITY JOURNAL; SEMANTICS; WORKING MEMORY; ALLELE; ALZHEIMER DISEASE; COGNITIVE DEFECT; COMPARATIVE STUDY; DISEASE COURSE; DRUG EFFECT; FOLLOW UP; GENETICS; NEUROPSYCHOLOGICAL TEST; PHYSIOLOGY; REACTION TIME; RECALL; REFERENCE VALUE;

AGED; AGED, 80 AND OVER; ALLELES; ALZHEIMER DISEASE; APOLIPOPROTEIN E2; APOLIPOPROTEIN E3; APOLIPOPROTEIN E4; APOLIPOPROTEINS E; COGNITION DISORDERS; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; GENE FREQUENCY; GENOTYPE; HUMANS; MALE; MENTAL RECALL; NEUROPSYCHOLOGICAL TESTS; REACTION TIME; REFERENCE VALUES;

EID: 0036884914     PISSN: 00223050     EISSN: None     Source Type: Journal    
DOI: 10.1136/jnnp.73.6.672     Document Type: Article

References (38)

1. Corder EH, Saunders AM, Strittmatter WJ, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 1993;261:921-3.
2. Saunders AM, Strittmatter WJ, Schmechel D, et al. Association of apolipoprotein E allele å4 with late-onset familial and sporadic Alzheimer's disease. Neurology 1993;43:1467-72.
3. Henderson AS, Easteal S, Jorm AF, et al. Apolipoprotein E allele ε4, dementia, and cognitive decline in a population sample. Lancet 1995;346:1387-90.
4. Riley KP, Snowdon DA, Saunders AM, et al. Cognitive function and apolipoprotein E in very old adults: Findings from the Nun Study. J Gerontol: Soc Sci 2000;55B:569-75.
5. Haan MN, Shemanski L, Jagust WJ, et al. The role of APOE ε4 in modulating effects of other risk factors for cognitive decline in elderly persons. JAMA 1999;282:40-6.
6. Mayeux R, Small SA, Tang M-X, et al. Memory performance in healthy elderly without Alzheimer's disease: Effects of time and apolipoprotein-E. Neurobiology of Aging 2001;22:683-9.
7. Wilson RS, Schneider JA, Barnes LL, et al. The apolipoprotein E ε4 allele and decline in different cognitive systems during a 6-year period. Arch Neurol 2002;59:1154-60.
8. Corder EH, Saunders AM, Risch NJ, et al. Protective effect of apoliporprotein E type 2 allele for late onset Alzheimer's disease. Nature Genet 1994;7:180-4.
9. Myers RH, Schaefer EJ, Wilson PWF, et al. Apolipoprotein E ε4 association with dementia in a population-based study: The Framingham study. Neurology 1996;46:673-7.
10. Helkala E-L, Koivisto K, Hanninen T, et al. Memory functions in human subjects with different apolipoprotein E phenotypes during a 3-year population-based follow-up study. Neurosci Lett 1996;204:177-80.
11. Hyman, BT, Gomez-Isla T, Briggs M, et al. Apolipoprotein E and cognitive change in an elderly population. Ann Neurol 1996;40:55-66.
12. Staehelin HB, Perrig-Chiello P, Mitrache C, et al. Apolipoprotein E genotypes and cognitive functions in healthy elderly persons. Acta Neurol Scand 1999;100:53-60.
13. Yaffe K, Cauley J, Sands L, et al. Apolipoprotein E phenotype and cognitive decline in a prospective study of elderly community women. Arch Neurol 1997;54:1110-14.
14. Bennett DA, Wilson RS, Schneider JA, et al. Natural history of mild cognitive impairment in older persons. Neurology 2002;59:198-205.
15. Wilson RS, Mendes de Leon CF, Barnes LL, et al. Participation in cognitively stimulating activities and risk of incident Alzheimer's disease. JAMA 2002;287:742-8.
16. Wilson RS, Schneider JA, Beckett LA, et al. Progression of gait disorder and rigidity and risk of death in older persons. Neurology 2002;58:1815-19.
17. Wilson RS, Beckett LA, Barnes LL, et al. Individual differences in rates of change in cognitive abilities of older persons. Psychol Aging 2002;17:179-93.
18. McKhann G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimer's disease: Report of the NINCDS/ADRDA work group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984;34:939-44.
19. Welsh KA, Butters N, Mohs RC, et al. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part V. A normative study of the neuropsychological battery. Neurology 1994;44:609-14.
20. Wechsler D. Wechsler Memory Scale-revised Manual. San Antonio, TX: Psychological Corporation, 1987.
21. Albert MS, Smith L, Scherr P, et al. Use of brief cognitive tests to identify individuals in the community with clinically diagnosed Alzheimer's disease. Int J Neurosci 1991;57:167-78.
22. Kaplan EF, Goodglass H, Weintraub S. The Boston Naming Test. 2nd Edn. Philadelphia: Lea and Febiger, 1983.
23. Nelson HE, National Adult Reading Test (NART): Test Manual. Windsor, Berkshire: NFER-NELSON Publishing, 1982.
24. Ekstrom RB, French JW, Harman HH, et al. Manual for Kit of Factor-referenced Cognitive Tests. Princeton, NJ: Educational Testing Service, 1976.
25. Cooper JA, Sagar HJ, Jordan N, et al. Cognitive impairment in early, untreated Parkinson's disease and its relationship to motor disability. Brain 1991;114:2095-122.
26. Craik FIM. A functional account of age differences in memory. In: Klix E, Hagendorf H, eds. Human Memory and Cognitive Capabilities: Mechanisms and Performances. Amsterdam: Elsevier Science, 1986:409-22.
27. Smith A. Symbol Digit Modalities Test Manual-revised. Los Angeles: Western Psychological Services, 1982.
28. Benton AL, Sivan AB, Hamsher K, et al. Contributions to Neuropsychological Assessment. 2nd Edn. New York: Oxford University Press, 1994.
29. Raven JC, Court JH, Raven J. Manual for Raven's Progressive Matrices and Vocabulary Scales. Oxford: Oxford University Press, 1992.
30. Hixson JE, Verneir DT. Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with Hha I. J Lipid Res 1990;31:545-8.
31. Cox DR. Regression models and life tables (with discussion). J Royal Star Soc B 1972;74:187-220.
32. Laird N, Ware J. Random-effects models for longitudinal data. Biometrics 1982;38:963-73.
33. SAS Institute Inc. SAS/STAT User's Guide, Version 8. Cary, NC: SAS Institute, 2000.
34. Evans DA, Beckett LA, Field TS, et al. Apolipoprotein E ε4 and incidence of Alzheimer's disease in a community population of older persons. JAMA 1997;277:822-4.
35. Slooter AJC, Cruts M, Kalmijn S, et al. Risk estimates of dementia by apolipoprotein E genotypes from a population-based incidence study: The Rotterdam study. Arch Neurol 1998;55:964-8.
36. Ordovas JM, Litwack-Klein L, Wilson PWF, et al. Apolipoprotein E isoform phenotyping methodology and population frequency with identification of apoE1 and apoE5 isoforms. J Lipid Res 1987;28:371-80.
37. Farrer LA, Cupples LA, Haines JL, et al. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer's disease: A meta-analysis. JAMA 1997;278:1349-56.
38. Arnold SE, Joe E, Martinoli M-G, et al. Apolipoprotein E genotype in schizophrenia: Frequency, age of onset, and neuropathologic features. Neuroreport 1997;8:1523-6.